A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) - Study Results

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety Study; Intervention Model: Crossover Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Chronic Obstructive Pulmonary Disease
Interventions:	Drug: Indacaterol 300 μg Drug: Placebo to indacaterol Drug: Salmeterol 50 μg

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Indacaterol 300 μg - Placebo to Indacaterol - Salmeterol 50 μg	In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Placebo to Indacaterol - Salmeterol 50 μg - Indacaterol 300 μg	In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Salmeterol 50 μg - Indacaterol 300 μg - Placebo to Indacaterol	In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Placebo to Indacaterol - Indacaterol 300 μg - Salmeterol 50 μg	In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Indacaterol 300 μg - Salmeterol 50 μg - Placebo to Indacaterol	In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Salmeterol 50 μg - Placebo to Indacaterol - Indacaterol 300 μg	In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Participant Flow for 3 periods

Period 1: Treatment Period 1

	Indacaterol 300 μg - Placebo to Indacaterol - Salmeterol 50 μg	Placebo to Indacaterol - Salmeterol 50 μg - Indacaterol 300 μg	Salmeterol 50 μg - Indacaterol 300 μg - Placebo to Indacaterol	Placebo to Indacaterol - Indacaterol 300 μg - Salmeterol 50 μg	Indacaterol 300 μg - Salmeterol 50 μg - Placebo to Indacaterol	Salmeterol 50 μg - Placebo to Indacaterol - Indacaterol 300 μg
STARTED	13	11	11	13	10	10
COMPLETED	13	10	10	13	9	10
NOT COMPLETED	0	1	1	0	1	0
Adverse Event	0	0	1	0	0	0
Withdrawal by Subject	0	1	0	0	0	0
Abnormal test procedure result(s)	0	0	0	0	1	0

Period 2: Treatment Period 2

	Indacaterol 300 μg - Placebo to Indacaterol - Salmeterol 50 μg	Placebo to Indacaterol - Salmeterol 50 μg - Indacaterol 300 μg	Salmeterol 50 μg - Indacaterol 300 μg - Placebo to Indacaterol	Placebo to Indacaterol - Indacaterol 300 μg - Salmeterol 50 μg	Indacaterol 300 μg - Salmeterol 50 μg - Placebo to Indacaterol	Salmeterol 50 μg - Placebo to Indacaterol - Indacaterol 300 μg
STARTED	13	10	10	13	9	10
COMPLETED	12	10	10	13	9	10
NOT COMPLETED	1	0	0	0	0	0
Adverse Event	1	0	0	0	0	0

Period 3: Treatment Period 3

	Indacaterol 300 μg - Placebo to Indacaterol - Salmeterol 50 μg	Placebo to Indacaterol - Salmeterol 50 μg - Indacaterol 300 μg	Salmeterol 50 μg - Indacaterol 300 μg - Placebo to Indacaterol	Placebo to Indacaterol - Indacaterol 300 μg - Salmeterol 50 μg	Indacaterol 300 μg - Salmeterol 50 μg - Placebo to Indacaterol	Salmeterol 50 μg - Placebo to Indacaterol - Indacaterol 300 μg
STARTED	12	10	10	13	9	10
COMPLETED	12	10	10	10	9	10
NOT COMPLETED	0	0	0	3	0	0
Adverse Event	0	0	0	2	0	0
Withdrawal by Subject	0	0	0	1	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Entire Study Population	The entire study population included all 6 treatment groups who received indacaterol 300 µg once daily, placebo to indacaterol once daily, and salmeterol 50 µg twice daily via a single-dose (indacaterol and placebo to indacaterol) or multi-dose (salmeterol) dry-powder inhaler in 6 different sequences. Patients received each treatment for 14 days with a 14 day washout between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Description

Entire Study Population

The entire study population included all 6 treatment groups who received indacaterol 300 µg once daily, placebo to indacaterol once daily, and salmeterol 50 µg twice daily via a single-dose (indacaterol and placebo to indacaterol) or multi-dose (salmeterol) dry-powder inhaler in 6 different sequences. Patients received each treatment for 14 days with a 14 day washout between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Baseline Measures

	Entire Study Population
Number of Participants [units: participants]	68
Age [units: years] Mean ± Standard Deviation	65.6 ± 9.03
Gender [units: participants]
Female	16
Male	52

Outcome Measures

Show All Outcome Measures

1. Primary:

Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Each Treatment Period (Day 15) [ Time Frame: After 14 days ]

Show Outcome Measure 1

2. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 5 Minutes Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 5 minutes post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 2

3. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 15 Minutes Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 15 minutes post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 3

4. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 30 Minutes Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 30 minutes post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 4

5. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 1 Hour Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 1 hour post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 5

6. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 2 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 2 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 6

7. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 3 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 3 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 7

8. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 4 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 4 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 8

9. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 5 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 5 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 9

10. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 6 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 6 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 10

11. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 8 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 8 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 11

12. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 10 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 10 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 12

13. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 11 Hours 10 Minutes Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 11 hours 10 minutes post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 13

14. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 11 Hours 45 Minutes Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 11 hours 45 minutes post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 14

15. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 14 Hours Post-dose at the End of Each Treatment Period (Day 14) [ Time Frame: 14 hours post-dose at the end of each treatment period (Day 14) ]

Show Outcome Measure 15

16. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 20 Hours 10 Minutes Post-dose at the End of Each Treatment Period (Day 15) [ Time Frame: 20 hours 10 minutes post-dose at the end of each treatment period (Day 15) ]

Show Outcome Measure 16

17. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 20 Hours 45 Minutes Post-dose at the End of Each Treatment Period (Day 15) [ Time Frame: 20 hours 45 minutes post-dose at the end of each treatment period (Day 15) ]

Show Outcome Measure 17

18. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 22 Hours Post-dose at the End of Each Treatment Period (Day 15) [ Time Frame: 22 hours post-dose at the end of each treatment period (Day 15) ]

Show Outcome Measure 18

19. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 23 Hours 10 Minutes Post-dose at the End of Each Treatment Period (Day 15) [ Time Frame: 23 hours 10 minutes post-dose at the end of each treatment period (Day 15) ]

Show Outcome Measure 19

20. Secondary:

Forced Expiratory Volume in 1 Second (FEV1) 23 Hours 45 Minutes Post-dose at the End of Each Treatment Period (Day 15) [ Time Frame: 23 hours 45 minutes post-dose at the end of each treatment period (Day 15) ]

Show Outcome Measure 20

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862 778-8300

No publications provided

Responsible Party:	External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00622635 History of Changes
Other Study ID Numbers:	CQAB149B2340
Study First Received:	February 4, 2008
Results First Received:	July 22, 2011
Last Updated:	July 22, 2011
Health Authority:	United States: Food and Drug Administration Spain: Spanish Agency of Medicines Belgium: Federal Agency for Medicinal Products and Health Products